<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) is associated with a large amount of <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, as it groups together a broad category of patients in whom various manifestations of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> are attributed to cerebrovascular or <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, a study was designed to determine the effects of rivastigmine on cognitive function, global daily living performance, and <z:hpo ids='HP_0000708'>behavioral disorders</z:hpo> in VaD patients versus an active control (nimodipine), stratifying patients according to the type of VaD, subcortical vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (sVAD), and multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> <z:hpo ids='HP_0000726'>dementia</z:hpo> (MID) </plain></SENT>
<SENT sid="2" pm="."><plain>The trial was a prospective study </plain></SENT>
<SENT sid="3" pm="."><plain>This study shows that long-term treatment with rivastigmine, at dosages approved for therapeutic use in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, produces significant improvement in <z:hpo ids='HP_0000001'>all</z:hpo> behavioral symptoms in 2 forms of VaD, MID and sVaD, except <z:hpo ids='HP_0000746'>delusions</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>It also suggests that rivastigmine may enable a reduction in concomitant <z:chebi fb="25" ids="35476">neuroleptics</z:chebi> and <z:chebi fb="13" ids="22720">benzodiazepines</z:chebi> in VaD, especially in MID </plain></SENT>
<SENT sid="5" pm="."><plain>The results are discussed with an overview of the literature </plain></SENT>
</text></document>